Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Gyre Therapeutics (GYRE) Net Income (2016 - 2026)

Gyre Therapeutics has reported Net Income over the past 16 years, most recently at -$22.1 million for Q4 2025.

Quarterly Net Income fell 1247.62% to -$22.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.9 million through Dec 2025, down 169.19% year-over-year, with the annual reading at -$10.9 million for FY2025, 169.19% down from the prior year.
Net Income was -$22.1 million for Q4 2025 at Gyre Therapeutics, down from $5.9 million in the prior quarter.
Over five years, Net Income peaked at $51.6 million in Q2 2022 and troughed at -$101.0 million in Q4 2023.
The 5-year median for Net Income is -$32000.0 (2024), against an average of -$8.2 million.
Year-over-year, Net Income surged 359.42% in 2022 and then crashed 1247.62% in 2025.
A 5-year view of Net Income shows it stood at -$20.4 million in 2021, then tumbled by 36.84% to -$27.9 million in 2022, then crashed by 261.95% to -$101.0 million in 2023, then soared by 98.38% to -$1.6 million in 2024, then crashed by 1247.62% to -$22.1 million in 2025.
Per Business Quant, the three most recent readings for GYRE's Net Income are -$22.1 million (Q4 2025), $5.9 million (Q3 2025), and $1.6 million (Q2 2025).